Grant List
Represents Grant table in the DB
GET /v1/grants?sort=-awardee_organization
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-awardee_organization", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=-awardee_organization", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=2&sort=-awardee_organization", "prev": null }, "data": [ { "type": "Grant", "id": "15649", "attributes": { "award_id": "2451399", "title": "SBIR Phase I: Novel Peptide Immunomodulators for Treatment of Autoimmune and Inflammatory Disorders", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Technology, Innovation and Partnerships (TIP)", "SBIR Phase I" ], "program_reference_codes": [], "program_officials": [ { "id": 936, "first_name": "Henry", "last_name": "Ahn", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-03-01", "end_date": null, "award_amount": 305000, "principal_investigator": { "id": 32152, "first_name": "Masha", "last_name": "Fridkis-Hareli", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2552, "ror": "", "name": "PALENA THERAPEUTICS, INC.", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is in developing a novel class of compounds capable of treating autoimmune and inflammatory conditions safely and effectively. With the constant threat of new COVID variants, influenza, and RSV, there is an unmet medical need for therapeutics that can effectively treat autoimmune diseases especially in pediatric patients without compromising the immune system to respond to infections. This problem has been overcome with the discovery of novel compositions that demonstrate efficacy equal or superior to many of the first line therapies used to treat immune diseases. The improved safety, efficacy and lower cost of these therapeutics should provide a significant benefit to patients by overall contributing to their quality of life as compared to current medications, as well as marketing and partnering advantage in its commercialization efforts, which will focus on rare diseases, such as juvenile idiopathic arthritis-associated uveitis and pediatric Crohn’s disease among others. In the era of socio-economic disparities, these affordable drugs will become available to the historically neglected low-income communities. If executed successfully, this proposal would validate the platform technology and demonstrate the feasibility of identifying candidates for further development into life-changing treatments. This Small Business Innovation Research (SBIR) Phase I project will demonstrate the unique design of novel compounds to augment and re-program the immune responses from pro- to anti-inflammatory, based on the binding to MHC class II molecules that leads to immunomodulation. The technical complexities of understanding the effects of peptide sequences on the outcomes of cellular interactions present challenges related to selecting the appropriate amino acids both for the random and specific components of these compositions. These hurdles will be addressed by design of several candidate compounds for each target condition, juvenile idiopathic arthritis-associated uveitis and pediatric Crohn’s disease, that will take into account the structure of autoantigenic peptides known to interact with both the MHC class II and T cell receptor (TCR). These candidate compounds will be initially tested in vitro in human macrophages to assess their potential to inhibit secretion of pro-inflammatory cytokines. Of these compounds, the most efficient ones will be tested for activity in relevant animal models. This approach will allow identifying and selecting the best drug candidates for further development into therapies for pediatric conditions as outlined above. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15627", "attributes": { "award_id": "1R43GM157920-01", "title": "Three-Dimensional Spatio-Temporal Control of Lipid Nanoparticle Manufacturing for Improved Nucleic Acid Delivery", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 31602, "first_name": "Sailaja", "last_name": "Koduri", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-01-01", "end_date": "2025-06-30", "award_amount": 306873, "principal_investigator": { "id": 32127, "first_name": "Po-Lun", "last_name": "Feng", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2551, "ror": "", "name": "OSEM FLUIDICS INC", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic has established the importance of nucleic acid-based lipid nanoparticles (LNPs) for the future of global health. The benefits of lipid nanoparticles are multifaceted as they protect sensitive pharmaceutical payloads from enzymatic degradation and allow for the modification of solubility, release kinetics, and bioavailability. While chemical formulation of LNPs has been widely explored, the effects of manufacturing—specifically microfluidics processing—are not currently well-understood. This knowledge gap presents challenges in the production of intricate nanoparticle structures, which require specialized microfluidic systems that produce well-defined and reproducible flow configurations. The proposed research focuses on developing 3D-printed channel architectures to precisely control LNP structure and properties to enhance transfection efficiency without modifying their chemical composition. Aim 1 involves designing, simulating, and testing various 3D channel architectures to manipulate flow conditions and tailor LNP properties. Aim 2 focuses on structural determination via SAXS and CryoTEM, and assesses the impact of LNP structures on mRNA transfection efficiency through in vitro transfection studies. Aim 3 will demonstrate the therapeutic- and disease-agnostic design workflow by robustly encapsulating siRNA and pDNA. This project aims to overcome the limitations of current LNP manufacturing methods which are constrained by fixed geometries and limited control over LNP assembly processes. Development of our enabling technology will offer an additional process parameter - channel architecture, for tuning LNP properties and structure in a rapid and customizable manner that is broadly applicable.", "keywords": [ "3-Dimensional", "3D Print", "Acceleration", "Address", "Affect", "Architecture", "Biological Availability", "COVID-19", "COVID-19 pandemic", "COVID-19 vaccine", "Characteristics", "Chemicals", "Chemistry", "Cholesterol", "Complex", "Development", "Devices", "Disease", "Encapsulated", "Formulation", "Foundations", "Future", "Gene Delivery", "Gene Expression", "Geometry", "Image", "In Vitro", "Kinetics", "Knowledge", "Lipids", "Liquid substance", "Messenger RNA", "Methods", "Microfabrication", "Microfluidic Microchips", "Microfluidics", "Modality", "Modification", "Nucleic Acids", "Outcome", "Pharmacologic Substance", "Phase", "Process", "Production", "Property", "Reproducibility", "Research", "Research Personnel", "Roentgen Rays", "Route", "SARS-CoV-2 spike protein", "Series", "Small Interfering RNA", "Solubility", "Structure", "System", "Technology", "Testing", "Therapeutic", "Time", "Transfection", "United States National Institutes of Health", "clinically relevant", "cost", "design", "experimental study", "fabrication", "fluid flow", "global health", "improved", "in vivo", "innovation", "interest", "lipid nanoparticle", "mRNA lipid nano particle vaccine", "manufacture", "manufacturing systems", "millimeter", "nanoparticle", "novel", "novel therapeutics", "nucleic acid delivery", "nucleic acid structure", "nucleic acid-based therapeutics", "operation", "particle", "pre-clinical", "prevent", "spatiotemporal", "therapeutic development", "tool" ], "approved": true } }, { "type": "Grant", "id": "15551", "attributes": { "award_id": "75N95024D00006-P00001-759502400001-1", "title": "TO1 - STSS PROGRAM SUPPORT 1.0", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-02-08", "end_date": "2024-05-31", "award_amount": 10367151, "principal_investigator": { "id": 26488, "first_name": "GARY", "last_name": "MAYS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2550, "ror": "", "name": "AXLE INFORMATICS, LLC", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "National COVID-19 Cohort Collaborative (N3C): The National COVID-19 Cohort Collaborative (N3C) sponsors the NIH COVID-19 Data Enclave, one of the largest data enclaves in the world supporting COVID-19 research. N3C is a partnership among the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs, with overall stewardship by NCATS. The N3C program consists of thousands of researchers, requiring enterprise level information technology (IT) support as part of a virtual research organization (VRO). This contract is necessary to ensure that NCATS and N3C can continue to provide adequate support for a secure, collaborative, VRO. This contract allows for continued support of the VRO which supports all of the required information technology functions to support an environment of over 4,000 users, including cloud-based productivity tools, a service desk, commercial and open-source deployments of analytical tools for the community to use, and expansion of the data types available for analysis, such as imaging, viral variant genomic sequences, etc. The common need is to share a collaborative cloud environment capable of ingesting billions of data points and performing a variety of complex analyses against multimodal data types, ranging from pathology and radiology data, synthetic data, genomic information, electronic health records (EHRs) and a wide variety of others. All of this must be done while meeting the highest levels of security and privacy, given the sensitivity of some of the data types being collected and the importance of the work being done in the environment. This contract provides support for all of these enterprise IT efforts.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15533", "attributes": { "award_id": "1R01AI186964-01", "title": "The role of cell, antigen, and antibody, in controlling virus infection through Fc-dependent mechanisms", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 29189, "first_name": "Moriah Jovita", "last_name": "Castleman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-12-23", "end_date": "2029-11-30", "award_amount": 318085, "principal_investigator": { "id": 32074, "first_name": "Ceri", "last_name": "Fielding", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 32075, "first_name": "Stephen", "last_name": "Graham", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 32076, "first_name": "Jordan Scott", "last_name": "Orange", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 32077, "first_name": "Richard", "last_name": "Stanton", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 32078, "first_name": "Eddie Chung Yern", "last_name": "Wang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 32079, "first_name": "Michael", "last_name": "Weekes", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 32080, "first_name": "Wioleta Milena", "last_name": "Zelek", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2549, "ror": "https://ror.org/03kk7td41", "name": "Cardiff University", "address": "", "city": "", "state": "", "zip": "", "country": "UNITED KINGDOM", "approved": true }, "abstract": "The ability of an�bodies to bind infected cells and ac�vate cellular immunity through an�body-dependent cellular cytotoxicity (ADCC), an�body-dependent cellular phagocytosis (ADCP), and complement-dependent cytolysis (CDC) is cri�cal to control of intracellular virus and intra-host dissemina�on. The induc�on of these responses is therefore highly desirable in an�viral and immunotherapeu�c responses. However, our understanding of how to exploit ADCC/ADCP/CDC significantly lags that of neutralising ac�vity. Whereas neutralising an�bodies can be readily induced by vaccina�on with entry glycoproteins or receptor-binding subdomains, it remains unclear how to select an�gens, domains, or epitopes, for op�mal ADCC ac�vity. We have shown that there is litle correla�on between the ability of an�bodies to neutralise and to ac�vate cellular immunity, and that previously unsuspected an�gens can induce significantly enhanced Fc-dependent ac�vity compared to those that induce neutralising responses. It is now cri�cal to understand why some an�gens and epitopes offer superior ac�va�on of cellular immunity. Our previous work required laborious wet-lab screening with ex vivo cells, virus infected cells, and proteomics, to iden�fy op�mal targets for this ac�vity. Deciphering the underlying biology of this process offers the poten�al to predict ideal an�gens and to design epitope-specific vaccina�on strategies, that maximise ADCC/ADCP/CDC responses in addi�on to neutralisa�on. This has the poten�al to enhance the efficacy of future vaccines and immunotherapies, as well as de-risk and accelerate their development. Fc-dependent immunity requires effector cell, an�body, epitope, and an�gen, to each co-ordinate. We therefore seek to understand how each of these aspects contributes to effec�ve control of intracellular virus. The molecular determinants that govern how NK cells control virus dissemina�on through ADCC will be assessed func�onally and through high- resolu�on imaging of the ADCC immunological synapse (IS), with proteomics used to determine why NK cells from different donors exhibit markedly different ADCC capaci�es. Molecular engineering of an�bodies will inves�gate the specificity requirements for ADCC responses, and methods of op�mising ADCC-inducing immunotherapies. Structural and IS-imaging studies will reveal how an�gen structure and epitope conforma�on affect ADCC efficacy, and whether the same requirements apply to the induc�on of ADCP and CDC. Finally, we will determine how predic�ons of Fc-dependent immunity can be rapidly validated. Although the way that these parameters interact is likely independent of any specific virus, viruses drama�cally remodel the infected cell surface to counteract host immunity and this can significantly alter the func�onal outcome of interac�ons. We will therefore use two different viruses throughout these studies – one which manipulates the surface proteome extensively (HCMV), and one less so (SARS-CoV-2) – to reveal whether virus immune-evasion impacts outcome, and whether any underlying principles are therefore virus-dependent. For both viruses we have iden�fied novel an�gens and monoclonals that provide enhanced ADCC responses as compared to current vaccine/immunotherapeu�c approaches.", "keywords": [ "2019-nCoV", "Acceleration", "Address", "Affect", "Ally", "Animal Model", "Antibodies", "Antigens", "Binding", "Biological Assay", "Biology", "Biophysics", "Cell surface", "Cell-Mediated Cytolysis", "Cells", "Cellular Immunity", "Complement", "Cytolysis", "Cytomegalovirus", "Data", "Development", "Disease", "Drama", "Effector Cell", "Engineering", "Epitopes", "Event", "Exhibits", "Fc Receptor", "Fc domain", "Future", "Glycoproteins", "Human", "Image", "Immune", "Immune Evasion", "Immunity", "Immunotherapy", "Knowledge", "Ligands", "Longevity", "Mediating", "Methods", "Molecular", "Natural Killer Cells", "Outcome", "Pathway interactions", "Persons", "Phagocytosis", "Phagocytosis Induction", "Process", "Proteins", "Proteome", "Proteomics", "Risk", "Role", "Specificity", "Structure", "Subunit Vaccines", "Surface", "Vaccines", "Viral", "Virus", "Virus Diseases", "Work", "assay development", "cell killing", "cell type", "design", "efficacy evaluation", "imaging study", "immunological synapse", "improved", "mutant", "novel", "pathogen", "receptor binding", "response", "screening", "single molecule", "tool", "tumor", "vaccine candidate", "vaccine development", "viral transmission" ], "approved": true } }, { "type": "Grant", "id": "15642", "attributes": { "award_id": "1R01HL176717-01", "title": "Aerocyte-mediated Alveolar Epithelial Regeneration following Lung Injury", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 23738, "first_name": "Sara", "last_name": "Lin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-01-16", "end_date": "2028-11-30", "award_amount": 480990, "principal_investigator": { "id": 32146, "first_name": "Bisheng", "last_name": "Zhou", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2548, "ror": "", "name": "UNIVERSITY OF ILLINOIS AT CHICAGO", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT Acute Respiratory Distress Syndrome (ARDS) is a life-threatening lung injury caused by various factors such as infection and trauma, currently lacking a cure. Annually, approximately 190,000 Americans are diagnosed with ARDS, a number further amplified by the COVID-19 pandemic. The primary pathology involves damage to the alveolar epithelium, necessitating innovative approaches to accelerate alveolar epithelial regeneration for treating ARDS. Alveoli, surrounded by abundant capillaries for gas exchange, remain poorly understood in their regulatory role within this intensive capillary niche. Our focus is on aerocytes, a recently identified capillary endothelial population specialized in the lungs and positioned on the outer surface of the alveolar epithelium. Given this unique location, we propose that aerocytes play a pivotal role in alveolar epithelial regeneration. Preliminary data indicate that aerocytes express the angiocrine factor R-spondin3, a Wnt signaling activator, and stem cell factor. Loss of angiocrine R-spondin3 impedes regenerative epithelial remodeling and lung repair following injury, suggesting a crucial role for aerocyte-derived signaling in lung alveolar regeneration. Our research proposal aims to establish the central role of aerocytes in regulating alveolar regeneration post lung injury, with a specific focus on the signaling molecule R-spondin3. We hypothesize that aerocytes guide regenerative alveolar remodeling through R-spondin3, enhancing Wnt signaling in alveolar epithelium, and orchestrating interstitial macrophage plasticity for the necessary regenerative niche. To rigorously test this hypothesis, we outline the following specific aims: Aim 1: Investigate the role of aerocyte-derived R-spondin3 in lung growth and recovery using loss-of- function and gain-of-function animal studies within disease-related lung injury models. Aim 2: Define the mechanisms of regenerative alveolar remodeling guided by aerocyte-derived signaling, focusing on AT2 cell renewal, transition into TSCs, and differentiation into AT1 cells using advanced techniques such as alveolar organoids. Aim 3: Examine the impact of aerocytes on interstitial macrophage plasticity in establishing a regenerative alveolar niche. By unveiling the role and mechanisms of aerocytes in alveolar epithelial regeneration, this research potentially leads to innovative therapeutic strategies for treating ARDS by targeting aerocyte-derived signaling to regenerate the alveoli, ultimately improving the health and quality of life for individuals affected by severe respiratory complications associated with COVID-19 and ARDS.", "keywords": [ "AGTR2 gene", "Acceleration", "Acute Lung Injury", "Acute Respiratory Distress Syndrome", "Address", "Affect", "Alveolar", "Alveolus", "American", "Animals", "Blood capillaries", "COVID-19 pandemic", "COVID-19/ARDS", "Cells", "Critical Illness", "Data", "Diagnosis", "Disease", "Endothelium", "Epithelium", "Gases", "Growth", "Health", "Individual", "Infection", "Injury", "Life", "Location", "Lung", "Macrophage", "Mediating", "Modeling", "Natural regeneration", "Organoids", "Pathology", "Play", "Population", "Positioning Attribute", "Quality of life", "Recovery", "Research", "Research Proposals", "Role", "Sepsis", "Signal Transduction", "Signaling Molecule", "Stem Cell Factor", "Surface", "Techniques", "Testing", "Therapeutic", "Trauma", "WNT Signaling Pathway", "alveolar epithelium", "effective intervention", "epithelium regeneration", "gain of function", "improved", "innovation", "interstitial", "loss of function", "lung injury", "lung repair", "new therapeutic target", "regenerative", "respiratory", "severe COVID-19" ], "approved": true } }, { "type": "Grant", "id": "15512", "attributes": { "award_id": "1R01NS135072-01A1", "title": "Targeting cerebrovascular Wnt/beta-catenin signaling to reverse brain endothelial damage induced by SARS-CoV-2 infection", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Neurological Disorders and Stroke (NINDS)" ], "program_reference_codes": [], "program_officials": [ { "id": 6896, "first_name": "WILLIAM PATRICK", "last_name": "Daley", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-12-01", "end_date": "2029-11-30", "award_amount": 801329, "principal_investigator": { "id": 31999, "first_name": "Sarah Elizabeth", "last_name": "Lutz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2548, "ror": "", "name": "UNIVERSITY OF ILLINOIS AT CHICAGO", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "Many COVID-19 survivors experience long-lasting neurological post-acute sequelae of COVID-19 (NeuroPASC) including cognitive, cerebrovascular, and neurological disorders. The causes of NeuroPASC are not understood. However, evidence suggests that blood-brain barrier damage may contribute to NeuroPASC. Identifying mechanisms that regulate the brain endothelial cell response in NeuroPASC is therefore important. Wnt/β-catenin signaling plays a critical role in maintaining integrity of the blood-brain barrier. This grant will test the novel mechanism that Wnt/β-catenin dysregulation in brain endothelial cells contributes to NeuroPASC by increasing blood-brain barrier permeability and neuroinflammation. We will determine the effect of age on brain endothelial cell signaling and blood-brain barrier permeability for the resolution of NeuroPASC. We will define the mechanism by which Wnt/β-catenin activation reverses blood-brain barrier leakage and memory impairment in NeuroPASC. We will determine the extent through which transcellular blood-brain barrier permeability contributes to NeuroPASC. These studies could identify future therapeutic strategies leveraging Wnt/β-catenin signaling to improve chronic post-infectious neurological diseases.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15504", "attributes": { "award_id": "75N91024P00404-0-0-1", "title": "NCI PATTERNS OF CARE STUDY- DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-05-01", "end_date": "2025-04-30", "award_amount": 86402, "principal_investigator": { "id": 32050, "first_name": "Marylou", "last_name": "Gonsalves", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2547, "ror": "", "name": "CONNECTICUT STATE DEPT OF PUBLIC HEALTH", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Cancer Institute (NCI) Patterns of Care (POC) studies describe, characterize, and compare practice patterns and treatments provided for cancer in different geographic areas of the United States. POC Studies are conducted periodically, typically annually, to satisfy a congressional directive (under Public Law 100-607, Sec. 413 (a)(2)(C) adopted on November 4, 1988) to the NCI to “assess the incorporation of state-of-the-art cancer treatments into clinical practice and the extent to which cancer patients receive such treatments and include the results of such assessment in the biennial reports…”. To satisfy the directive and to update and enhance the utility of the POC Studies, a working group including representatives from the NCI’s Divisions of Cancer Control and Population Sciences and Cancer Treatment and Diagnosis and a representative from the American Cancer Society was developed to review knowledge gaps in cancer therapy dissemination and to develop priority areas for study. The group reached a consensus that a gap remains regarding factors associated with guideline use of biomarker tests and targeted therapy. Furthermore, the group determined there is limited information about the effects of the COVID-19 pandemic on cancer screening, diagnosis, treatment, and receipt of supportive/palliative care among individuals diagnosed with cancer. For feasibility reasons, the group also recommended that this POC Study be focused specifically on the patterns of care for patients newly diagnosed with prostate or ovarian cancer. This POC Study will also collect data on documentation of palliative care and patient financial impacts of the COVID-19 pandemic. Relevant information on cancer diagnosis, cancer recurrence and metastasis, patterns of care (e.g., utilization of biomarker testing, specific cancer treatments, supportive/palliative care), and patient financial stability shall be abstracted from medical records among patients aged 20 years or older who were diagnosed with prostate or ovarian cancer in 2021.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15489", "attributes": { "award_id": "75N93024C00014-0-9999-1", "title": "MRNA VACCINE DEVELOPMENT", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-09-01", "end_date": "2026-08-31", "award_amount": 594566, "principal_investigator": { "id": 32041, "first_name": "KATERINA", "last_name": "ANDRIANOVA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2546, "ror": "", "name": "FLAG BIO, INC.", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The contractor will develop mRNAFlag as a vaccine adjuvant. mRNAFlag is an mRNA transcript that encodes for the deimmunized TLR5 agonist GP532. mRNAFlag would be developed within the context of an influenza mRNA vaccine, using an A/California/07/2009(H1N1) hemagglutinin in an LNP formulation used by Moderna for its SARS-CoV-2 vaccine.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15488", "attributes": { "award_id": "1I01BX006139-01A1", "title": "Junctophilin- 2 in brown Adipocyte Metabolic Regulation and Obesity", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2024-10-01", "end_date": "2028-09-30", "award_amount": null, "principal_investigator": { "id": 32040, "first_name": "Long-Sheng", "last_name": "Song", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2545, "ror": "https://ror.org/03r9k1585", "name": "Iowa City VA Medical Center", "address": "", "city": "", "state": "IA", "zip": "", "country": "United States", "approved": true }, "abstract": "Obesity, a state of imbalance between caloric intake and energy expenditure, is a major global problem that increases the risk of developing a wide range of diseases including insulin resistance, type 2 diabetes, cardiovascular disease and COVID-19 among others. Brown adipocytes in brown adipose tissue (BAT) depots dissipate chemical energy in the form of heat through non-shivering thermogenesis, to increase systemic energy expenditure and maintain whole-body energy homeostasis in response to stresses, including cold exposure and overnutrition. Brown adipocytes share a common lineage with muscle cells, the source of shivering thermogenesis. We recently discovered that junctophilin-2 (JP2), a muscle specific protein, is also enriched in brown adipocytes. JP2 is a structural protein that spatially organizes endo/sarcoplasmic reticulum (ER/SR)-plasma membrane (PM) junctions in muscle cells. These EM/SR-PM junctions are essential for precise control of Ca2+ homeostasis and contractile function in cardiac and skeletal muscles. In addition to its structural role, we recently demonstrated that JP2 serves as a stress-adaptive transcriptional regulator, controlling the transcriptome that regulates metabolic pathways that are also relevant to adipose metabolism. However, it remains completely unknown whether JP2 also functions in regulating Ca2+ homeostasis, and thermogenic program in brown adipocytes. In pilot studies, JP2 expression in BAT was suppressed by diet-induced obesity. Furthermore, JP2 deficiency disrupts BAT calcium dynamics and blunts sympathetic nervous system activation of thermogenesis in BAT. Notably, adipose-specific JP2 deletion promotes cold intolerance, and worsens obesity-associated metabolic dysfunction. These pilot data indicate that JP2 is required for maintaining thermogenic and metabolic homeostasis in BAT. Based on these intriguing preliminary data, we hypothesize that JP2 is crucial in maintaining normal Ca2+ homeostasis and energy metabolism in brown adipocytes, and defects in JP2-mediated Ca2+ regulation lead to energy imbalance and metabolic dysfunction. To test this hypothesis, we will use a multidisciplinary approach, including multiple novel mouse models, high resolution confocal imaging, patch-clamp electrophysiology, cellular and molecular biology, biochemical analysis and a spectrum of in vitro and in vivo metabolic assays. Upon successful completion of this project, we will establish a mechanistic understanding of the physiological regulation of JP2 in brown adipocytes and the pathophysiological role of JP2 dysregulation in obesity and associated diseases, therefore revealing a novel molecular mechanism leading to metabolic disorders.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15484", "attributes": { "award_id": "1R41MD019586-01", "title": "MiREA, a mHealth intervention to Reduce Health Disparities by Improving Equitable Access to Mandated College Students with Problematic Alcohol and Marijuana Use", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 6029, "first_name": "JARRETT AINSWORTH", "last_name": "Johnson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-11-01", "end_date": "2025-10-31", "award_amount": 296519, "principal_investigator": { "id": 32039, "first_name": "Donna Marie", "last_name": "Kazemi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2544, "ror": "", "name": "MHEALTH SYSTEMS, INC", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "This STTR Phase I proposal is designed to address the urgent need for an effective primary prevention approach to the problem of heavy episodic drinking and cannabis misuse among mandated minority college students attending Historically Black Colleges and Universities (HBCUs) and attending school in rural Appalachian Regional Commission (ARC) counties. Alcohol and cannabis misuse affects all demographic groups in the United States (NSDUH, 2021); however, some subsets are disproportionally affected. Access to treatment differs, often by race and gender. With growing evidence of health disparities among minority college students, the COVID-19 pandemic has decimated college budgets and elevated the risk of substance misuse and mental health issues. Smartphone app interventions are expanding and can offer accessible, scalable, and cost-effective tools. Cannabis use has increased significantly among Hispanic and Black Americans aged 18 and up in 2015-2018 (NSDUH, 2020). Alcohol death rates among college-age students (18 to 34) jumped 69% from 2007 to 2020. Cannabis is the most widely used illicit drug among the country's 20- plus million college students. Research suggests that newer technologies, such as smartphone apps, prevent misuse in mandated students more effectively than face-to-face intervention. However, little research has been done into culturally attuned evidence-based interventions that empower students to engage in health-seeking behaviors and avoid risky alcohol and cannabis misuse. To address this gap, mHealth Systems, Inc. is partnering with the University of NC at Charlotte (UNCC), the University of South Carolina USC), and Harvard Medical School Teaching Hospital on this Phase I STTR. We will enhance the Motivational Intervention in Real-time delivered through the Ecological Application (MiREA) App by expanding to incorporate further culturally attuned content. Phase 1 will test the adapted product's feasibility and acceptability. Specific aims: 1) Determine usability, feasibility, and efficacy of the MiREA-AC intervention (months 1-12); we will: a) conduct alpha theater and field testing (months 1-3, n=10) at two U.S. campuses to ensure acceptability of the app's contents; b) conduct a multi-site pilot feasibility trial (months 3-12, n=60) at six U.S. campuses. 2) Examine key customer needs by engaging with a Stakeholders Advisory Board (SAB, n=50, months 1-12) composed of health wellness staff, administrators, and minority representatives from HBCU and ARC socioeconomically disadvantaged colleges and universities and engage the SAB in the integration of MiREA-AC prototype within mandated programs. Participants will include 60 minority-mandated students from six US universities, ages 18 to 25, who have violated school drug and alcohol policies. Because of students' comfort with mobile technologies, we expect those receiving digital intervention to report higher satisfaction with the MiREA-AC mobile app than with in-person interventions. We expect MiREA-AC to be more cost-effective and to have greater reach, adoptability, portability, and sustainability than current approaches.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1, "pages": 1392, "count": 13920 } } }